We observed that I-BET762 treatment inhibits MYC expression accompanied by the growth inhibition and decreased survival in prostate cancer cells that over-express MYC. Importantly, BET inhibition reduces tumor burden in a primary model of castration resistant prostate cancer that expresses high levels of MYC. Our data suggest that BET inhibitors offer new therapeutic approach to treat prostate tumors driven by MYC. The gene discussed is MYC; the disease is prostate cancer.